Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Invested Capital (2024 - 2025)

Prelude Therapeutics' Invested Capital history spans 2 years, with the latest figure at $68.6 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 47.79% year-over-year to $68.6 million; the TTM value through Dec 2025 reached $68.6 million, down 47.79%, while the annual FY2025 figure was $68.6 million, 47.79% down from the prior year.
  • Invested Capital for Q4 2025 was $68.6 million at Prelude Therapeutics, up from $58.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $210.7 million in Q1 2024 and bottomed at $58.5 million in Q3 2025.